| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydatidiform Mole | 140 | 2024 | 255 | 21.860 |
Why?
|
| Uterine Neoplasms | 195 | 2024 | 1424 | 16.060 |
Why?
|
| Chorionic Gonadotropin | 75 | 2024 | 458 | 5.740 |
Why?
|
| Choriocarcinoma | 42 | 2022 | 121 | 4.650 |
Why?
|
| Trophoblastic Neoplasms | 68 | 2000 | 89 | 4.420 |
Why?
|
| Methotrexate | 39 | 2024 | 1721 | 4.400 |
Why?
|
| Ovarian Neoplasms | 143 | 2021 | 4915 | 3.690 |
Why?
|
| Pregnancy | 277 | 2024 | 30260 | 3.610 |
Why?
|
| Vacuum Curettage | 7 | 2021 | 44 | 2.620 |
Why?
|
| Dactinomycin | 28 | 2024 | 305 | 2.530 |
Why?
|
| Trophoblastic Tumor, Placental Site | 8 | 2024 | 21 | 2.140 |
Why?
|
| Brazil | 18 | 2023 | 1250 | 2.100 |
Why?
|
| Hysterectomy | 30 | 2024 | 863 | 2.030 |
Why?
|
| Placenta | 26 | 2022 | 1725 | 1.900 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 48 | 2024 | 11873 | 1.880 |
Why?
|
| Antimetabolites, Antineoplastic | 10 | 2020 | 646 | 1.530 |
Why?
|
| Pregnancy Outcome | 17 | 2021 | 2972 | 1.440 |
Why?
|
| Female | 478 | 2024 | 397113 | 1.380 |
Why?
|
| Pregnancy Complications, Neoplastic | 11 | 2017 | 260 | 1.370 |
Why?
|
| Neoplasm Staging | 73 | 2021 | 11221 | 1.340 |
Why?
|
| Neoplasms, Glandular and Epithelial | 14 | 2018 | 489 | 1.250 |
Why?
|
| Uterine Hemorrhage | 11 | 2017 | 236 | 1.250 |
Why?
|
| Leucovorin | 18 | 2021 | 643 | 1.200 |
Why?
|
| Etoposide | 15 | 2024 | 640 | 1.120 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 14 | 2015 | 83 | 1.090 |
Why?
|
| Cystadenocarcinoma, Serous | 19 | 2020 | 480 | 1.050 |
Why?
|
| Trophoblasts | 11 | 2017 | 223 | 1.040 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2018 | 287 | 1.040 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2023 | 5335 | 1.010 |
Why?
|
| Humans | 482 | 2024 | 767991 | 0.940 |
Why?
|
| Fallopian Tube Neoplasms | 14 | 2020 | 329 | 0.940 |
Why?
|
| Neoplasm Recurrence, Local | 38 | 2023 | 9412 | 0.910 |
Why?
|
| Retrospective Studies | 91 | 2024 | 81746 | 0.880 |
Why?
|
| Maternal Age | 6 | 2016 | 805 | 0.880 |
Why?
|
| Watchful Waiting | 2 | 2017 | 492 | 0.840 |
Why?
|
| New England | 16 | 2017 | 1058 | 0.830 |
Why?
|
| Hyperthyroidism | 3 | 2022 | 292 | 0.810 |
Why?
|
| Adult | 192 | 2024 | 223583 | 0.800 |
Why?
|
| Dilatation and Curettage | 9 | 2012 | 53 | 0.760 |
Why?
|
| Adenocarcinoma, Clear Cell | 11 | 2020 | 218 | 0.760 |
Why?
|
| Peritoneal Neoplasms | 19 | 2020 | 707 | 0.700 |
Why?
|
| Endometrial Neoplasms | 14 | 2020 | 1382 | 0.690 |
Why?
|
| Cohort Studies | 30 | 2023 | 41749 | 0.660 |
Why?
|
| Remission Induction | 16 | 2020 | 2409 | 0.640 |
Why?
|
| Fallopian Tube Diseases | 2 | 2016 | 60 | 0.630 |
Why?
|
| Ovary | 16 | 2018 | 965 | 0.620 |
Why?
|
| Antineoplastic Agents | 30 | 2021 | 13658 | 0.620 |
Why?
|
| Young Adult | 34 | 2024 | 60048 | 0.610 |
Why?
|
| Uterine Cervical Neoplasms | 15 | 2021 | 2043 | 0.610 |
Why?
|
| Curettage | 3 | 2016 | 74 | 0.600 |
Why?
|
| Fallopian Tubes | 5 | 2018 | 179 | 0.590 |
Why?
|
| Cyclophosphamide | 15 | 2023 | 2227 | 0.590 |
Why?
|
| Vulvar Neoplasms | 7 | 2018 | 266 | 0.560 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2017 | 190 | 0.560 |
Why?
|
| Genital Neoplasms, Female | 6 | 2013 | 536 | 0.550 |
Why?
|
| Hypothyroidism | 1 | 2022 | 667 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 26 | 2020 | 8637 | 0.540 |
Why?
|
| Vincristine | 7 | 2023 | 1040 | 0.540 |
Why?
|
| Cysts | 1 | 2022 | 685 | 0.530 |
Why?
|
| Hungary | 6 | 2016 | 82 | 0.530 |
Why?
|
| CA-125 Antigen | 8 | 2020 | 281 | 0.530 |
Why?
|
| Cystadenocarcinoma, Papillary | 10 | 2012 | 56 | 0.530 |
Why?
|
| Drug Substitution | 1 | 2019 | 291 | 0.520 |
Why?
|
| Neoplasms, Multiple Primary | 6 | 2017 | 594 | 0.520 |
Why?
|
| Adolescent | 61 | 2021 | 89155 | 0.510 |
Why?
|
| Risk Factors | 56 | 2024 | 74936 | 0.490 |
Why?
|
| Prognosis | 57 | 2024 | 29979 | 0.480 |
Why?
|
| Carcinoma in Situ | 7 | 2018 | 788 | 0.470 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 4 | 2019 | 195 | 0.460 |
Why?
|
| Adenocarcinoma, Mucinous | 13 | 2020 | 524 | 0.460 |
Why?
|
| DNA, Neoplasm | 18 | 2017 | 1742 | 0.450 |
Why?
|
| Middle Aged | 140 | 2024 | 223422 | 0.450 |
Why?
|
| Matrix Metalloproteinases | 2 | 2011 | 393 | 0.450 |
Why?
|
| Carcinoma | 15 | 2019 | 2330 | 0.440 |
Why?
|
| Immunohistochemistry | 30 | 2018 | 11068 | 0.440 |
Why?
|
| South America | 3 | 2020 | 180 | 0.440 |
Why?
|
| Interferon Type I | 1 | 2017 | 569 | 0.420 |
Why?
|
| Sialoglycoproteins | 5 | 2006 | 316 | 0.410 |
Why?
|
| p21-Activated Kinases | 1 | 2013 | 127 | 0.410 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 2 | 2011 | 97 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2013 | 145 | 0.410 |
Why?
|
| Loss of Heterozygosity | 15 | 2012 | 663 | 0.390 |
Why?
|
| Endometriosis | 4 | 2016 | 873 | 0.380 |
Why?
|
| Carboplatin | 10 | 2019 | 791 | 0.370 |
Why?
|
| Prenatal Diagnosis | 2 | 2018 | 1275 | 0.370 |
Why?
|
| Abortion, Induced | 1 | 2017 | 471 | 0.360 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2004 | 1059 | 0.360 |
Why?
|
| Pre-Eclampsia | 4 | 2017 | 1257 | 0.360 |
Why?
|
| Metrorrhagia | 1 | 2010 | 17 | 0.350 |
Why?
|
| Pregnancy, Multiple | 4 | 2017 | 216 | 0.340 |
Why?
|
| Neutrophils | 1 | 2022 | 3786 | 0.340 |
Why?
|
| Ovarian Cysts | 5 | 2020 | 108 | 0.330 |
Why?
|
| Stillbirth | 3 | 2021 | 381 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 3514 | 0.320 |
Why?
|
| Neoplasm, Residual | 6 | 2021 | 1014 | 0.310 |
Why?
|
| MicroRNAs | 7 | 2020 | 3804 | 0.310 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 662 | 0.310 |
Why?
|
| Fertility | 3 | 2010 | 771 | 0.310 |
Why?
|
| RNA, Neoplasm | 6 | 2020 | 748 | 0.300 |
Why?
|
| Gravidity | 3 | 2021 | 50 | 0.300 |
Why?
|
| Treatment Outcome | 32 | 2022 | 65364 | 0.290 |
Why?
|
| Combined Modality Therapy | 20 | 2016 | 8535 | 0.290 |
Why?
|
| Risk | 15 | 2022 | 9609 | 0.290 |
Why?
|
| Drug Administration Schedule | 10 | 2021 | 4857 | 0.280 |
Why?
|
| Disease Management | 4 | 2024 | 2533 | 0.270 |
Why?
|
| Gestational Age | 10 | 2021 | 3622 | 0.270 |
Why?
|
| Ultrasonography, Prenatal | 6 | 2009 | 1772 | 0.270 |
Why?
|
| Lung Neoplasms | 7 | 2021 | 13499 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2021 | 3553 | 0.270 |
Why?
|
| Antigens | 3 | 2008 | 1442 | 0.260 |
Why?
|
| Thoracotomy | 1 | 2008 | 374 | 0.260 |
Why?
|
| Neoplasm Metastasis | 18 | 2014 | 4904 | 0.260 |
Why?
|
| Epithelial Cells | 12 | 2018 | 3703 | 0.260 |
Why?
|
| Immunity, Cellular | 4 | 2010 | 1561 | 0.260 |
Why?
|
| Isoenzymes | 4 | 2013 | 1688 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2018 | 2846 | 0.260 |
Why?
|
| Abortion, Spontaneous | 4 | 2021 | 534 | 0.250 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5520 | 0.250 |
Why?
|
| Papillomavirus Infections | 4 | 2021 | 1640 | 0.250 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 13 | 2015 | 3798 | 0.240 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2253 | 0.240 |
Why?
|
| Apoptosis | 7 | 2020 | 9521 | 0.240 |
Why?
|
| Adenocarcinoma | 12 | 2019 | 6371 | 0.240 |
Why?
|
| Cross-Sectional Studies | 9 | 2023 | 26375 | 0.240 |
Why?
|
| Chorionic Villi | 4 | 2017 | 53 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 20 | 2020 | 6119 | 0.230 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 812 | 0.230 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 3231 | 0.230 |
Why?
|
| Carcinosarcoma | 2 | 2015 | 108 | 0.230 |
Why?
|
| Alcohol Oxidoreductases | 2 | 2016 | 164 | 0.230 |
Why?
|
| Microvessels | 1 | 2008 | 585 | 0.220 |
Why?
|
| Chromosome Deletion | 7 | 2000 | 1384 | 0.220 |
Why?
|
| Cell Line, Tumor | 18 | 2018 | 17128 | 0.220 |
Why?
|
| Overweight | 1 | 2015 | 2448 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2019 | 4050 | 0.220 |
Why?
|
| Carcinoma, Papillary | 4 | 2013 | 792 | 0.220 |
Why?
|
| Paget Disease, Extramammary | 2 | 2018 | 50 | 0.220 |
Why?
|
| Cisplatin | 7 | 2016 | 1658 | 0.220 |
Why?
|
| Genes, p53 | 9 | 2010 | 711 | 0.220 |
Why?
|
| Cell Adhesion Molecules | 5 | 2016 | 1613 | 0.220 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 321 | 0.220 |
Why?
|
| RNA, Messenger | 23 | 2018 | 12797 | 0.220 |
Why?
|
| Cellular Structures | 1 | 2022 | 9 | 0.210 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2020 | 681 | 0.210 |
Why?
|
| Paclitaxel | 10 | 2016 | 1728 | 0.210 |
Why?
|
| Registries | 9 | 2024 | 8377 | 0.210 |
Why?
|
| North America | 2 | 2017 | 1289 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 19 | 2018 | 3618 | 0.210 |
Why?
|
| Ploidies | 6 | 2010 | 287 | 0.200 |
Why?
|
| Antigens, Neoplasm | 9 | 2013 | 1997 | 0.200 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3115 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 16 | 2016 | 4576 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3238 | 0.200 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2023 | 156 | 0.200 |
Why?
|
| Growth Substances | 1 | 2004 | 759 | 0.200 |
Why?
|
| Fertilization | 1 | 2023 | 197 | 0.190 |
Why?
|
| Follow-Up Studies | 27 | 2020 | 39345 | 0.190 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2014 | 275 | 0.190 |
Why?
|
| Papillomaviridae | 4 | 2019 | 1140 | 0.190 |
Why?
|
| Aged | 77 | 2021 | 171446 | 0.190 |
Why?
|
| Blood Cell Count | 1 | 2022 | 406 | 0.190 |
Why?
|
| Lutein | 1 | 2022 | 123 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 8 | 2021 | 2902 | 0.190 |
Why?
|
| Neoplasm Proteins | 8 | 2006 | 3601 | 0.190 |
Why?
|
| Live Birth | 2 | 2017 | 516 | 0.190 |
Why?
|
| Genes, ras | 6 | 2001 | 657 | 0.190 |
Why?
|
| Cervix Uteri | 3 | 2021 | 577 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 23 | 2017 | 6071 | 0.190 |
Why?
|
| Tumor Virus Infections | 2 | 2002 | 437 | 0.190 |
Why?
|
| Gynecology | 3 | 2016 | 534 | 0.180 |
Why?
|
| Genes, BRCA1 | 5 | 2013 | 755 | 0.180 |
Why?
|
| HLA Antigens | 8 | 1986 | 1334 | 0.180 |
Why?
|
| Osteonectin | 2 | 2001 | 33 | 0.180 |
Why?
|
| Bleomycin | 4 | 2012 | 492 | 0.180 |
Why?
|
| Telemedicine | 1 | 2018 | 3109 | 0.180 |
Why?
|
| Lymphocytes | 3 | 2022 | 2614 | 0.180 |
Why?
|
| Hysteroscopy | 1 | 2021 | 62 | 0.180 |
Why?
|
| Uterine Artery | 1 | 2020 | 29 | 0.180 |
Why?
|
| Growth Differentiation Factor 2 | 1 | 2020 | 27 | 0.180 |
Why?
|
| Uterus | 5 | 2012 | 663 | 0.180 |
Why?
|
| Disease-Free Survival | 12 | 2021 | 6843 | 0.170 |
Why?
|
| Semen | 1 | 2023 | 349 | 0.170 |
Why?
|
| Heat-Shock Proteins | 2 | 2004 | 797 | 0.170 |
Why?
|
| X-Rays | 1 | 2021 | 311 | 0.170 |
Why?
|
| Survival Rate | 13 | 2020 | 12828 | 0.170 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 1998 | 301 | 0.170 |
Why?
|
| Aged, 80 and over | 34 | 2021 | 59598 | 0.170 |
Why?
|
| Arteriovenous Malformations | 1 | 2003 | 396 | 0.170 |
Why?
|
| Treatment Refusal | 1 | 2003 | 433 | 0.170 |
Why?
|
| Mixed Tumor, Mullerian | 3 | 2004 | 55 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2021 | 1168 | 0.170 |
Why?
|
| Community Health Centers | 1 | 2023 | 469 | 0.170 |
Why?
|
| Iodide Peroxidase | 1 | 2021 | 295 | 0.170 |
Why?
|
| Vitamin A | 2 | 2020 | 611 | 0.160 |
Why?
|
| Genes, erbB-1 | 1 | 2000 | 161 | 0.160 |
Why?
|
| Cell Proliferation | 9 | 2020 | 10470 | 0.160 |
Why?
|
| Infusions, Intravenous | 4 | 2017 | 2227 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 1999 | 149 | 0.160 |
Why?
|
| Gene Expression Profiling | 13 | 2017 | 9536 | 0.160 |
Why?
|
| Fluorescent Antibody Technique | 12 | 2016 | 2473 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2020 | 1405 | 0.160 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 3237 | 0.160 |
Why?
|
| Angiopoietin-2 | 2 | 2012 | 186 | 0.160 |
Why?
|
| Immunotherapy | 4 | 2024 | 4748 | 0.160 |
Why?
|
| Cell Line | 13 | 2017 | 15597 | 0.160 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2008 | 2568 | 0.160 |
Why?
|
| Ostomy | 1 | 2019 | 33 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 2 | 2010 | 2630 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 353 | 0.160 |
Why?
|
| Contraceptive Devices, Female | 2 | 2017 | 39 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2018 | 2953 | 0.160 |
Why?
|
| Time Factors | 23 | 2020 | 40214 | 0.160 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1999 | 108 | 0.160 |
Why?
|
| BRCA1 Protein | 6 | 2013 | 1155 | 0.150 |
Why?
|
| Endometrium | 3 | 1994 | 406 | 0.150 |
Why?
|
| Ovariectomy | 7 | 2013 | 613 | 0.150 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 3 | 1993 | 138 | 0.150 |
Why?
|
| Predictive Value of Tests | 14 | 2017 | 15442 | 0.150 |
Why?
|
| Age Factors | 12 | 2016 | 18407 | 0.150 |
Why?
|
| Organoids | 2 | 2018 | 743 | 0.150 |
Why?
|
| Thyrotropin | 1 | 2022 | 835 | 0.150 |
Why?
|
| Pregnancy, Tubal | 1 | 1998 | 15 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 706 | 0.150 |
Why?
|
| Medical Records | 6 | 2006 | 1409 | 0.150 |
Why?
|
| Diagnosis, Differential | 15 | 2020 | 13000 | 0.150 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 53 | 0.150 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 219 | 0.150 |
Why?
|
| Mullerian Ducts | 2 | 2016 | 203 | 0.150 |
Why?
|
| Disease Progression | 7 | 2021 | 13665 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2017 | 249 | 0.150 |
Why?
|
| Folic Acid Antagonists | 1 | 1998 | 74 | 0.150 |
Why?
|
| Ascitic Fluid | 1 | 2018 | 189 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 6 | 4 | 2001 | 370 | 0.140 |
Why?
|
| Precancerous Conditions | 4 | 2018 | 984 | 0.140 |
Why?
|
| Killer Cells, Natural | 6 | 2022 | 2211 | 0.140 |
Why?
|
| Enterotoxins | 2 | 2010 | 366 | 0.140 |
Why?
|
| Brachytherapy | 3 | 2015 | 1220 | 0.140 |
Why?
|
| Endometrial Hyperplasia | 2 | 1995 | 102 | 0.140 |
Why?
|
| Cyclin A1 | 1 | 2016 | 11 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 11 | 2017 | 9252 | 0.140 |
Why?
|
| Organoplatinum Compounds | 3 | 2013 | 406 | 0.140 |
Why?
|
| Nuclear Proteins | 4 | 2016 | 5799 | 0.140 |
Why?
|
| DNA-Binding Proteins | 5 | 2016 | 9614 | 0.130 |
Why?
|
| Gene Expression | 9 | 2016 | 7597 | 0.130 |
Why?
|
| Serum | 1 | 2017 | 206 | 0.130 |
Why?
|
| Sensitivity and Specificity | 11 | 2021 | 14718 | 0.130 |
Why?
|
| Logistic Models | 5 | 2018 | 13289 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2016 | 1120 | 0.130 |
Why?
|
| Ascites | 1 | 2018 | 338 | 0.130 |
Why?
|
| Pulmonary Embolism | 3 | 2019 | 2599 | 0.130 |
Why?
|
| Obesity | 3 | 2015 | 13091 | 0.130 |
Why?
|
| Genetic Markers | 8 | 2020 | 2602 | 0.130 |
Why?
|
| Embolization, Therapeutic | 2 | 2003 | 1403 | 0.130 |
Why?
|
| Doxorubicin | 8 | 2020 | 2234 | 0.130 |
Why?
|
| Cloning, Molecular | 3 | 1999 | 4168 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 904 | 0.130 |
Why?
|
| Antibodies, Neoplasm | 2 | 2010 | 283 | 0.120 |
Why?
|
| Incidence | 9 | 2016 | 21532 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 2 | 1998 | 4525 | 0.120 |
Why?
|
| Remote Consultation | 1 | 2018 | 242 | 0.120 |
Why?
|
| Case-Control Studies | 12 | 2020 | 22287 | 0.120 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2016 | 200 | 0.120 |
Why?
|
| Teratoma | 1 | 2018 | 405 | 0.120 |
Why?
|
| Multivariate Analysis | 8 | 2020 | 12075 | 0.120 |
Why?
|
| Fetal Death | 1 | 2017 | 434 | 0.120 |
Why?
|
| Contraceptives, Oral | 4 | 2009 | 560 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 5 | 1998 | 418 | 0.120 |
Why?
|
| RNA Precursors | 1 | 2016 | 196 | 0.120 |
Why?
|
| Parity | 5 | 2016 | 931 | 0.120 |
Why?
|
| Pregnancy Trimester, First | 4 | 2000 | 917 | 0.120 |
Why?
|
| Sexual Partners | 1 | 1999 | 805 | 0.120 |
Why?
|
| Referral and Consultation | 4 | 2021 | 3619 | 0.120 |
Why?
|
| Brain Neoplasms | 8 | 2024 | 9116 | 0.120 |
Why?
|
| Ribonuclease III | 1 | 2016 | 271 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 4 | 2008 | 1061 | 0.110 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2013 | 42 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3669 | 0.110 |
Why?
|
| DNA, Complementary | 7 | 2005 | 1989 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2008 | 10264 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2016 | 730 | 0.110 |
Why?
|
| Laparoscopy | 6 | 2015 | 2042 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 575 | 0.110 |
Why?
|
| Colectomy | 1 | 2019 | 696 | 0.110 |
Why?
|
| Obstetrics | 2 | 2016 | 681 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2019 | 6517 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1995 | 342 | 0.110 |
Why?
|
| Antigen-Antibody Complex | 6 | 1986 | 513 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2016 | 385 | 0.110 |
Why?
|
| DNA Helicases | 1 | 1999 | 854 | 0.110 |
Why?
|
| World Health Organization | 2 | 2016 | 1328 | 0.110 |
Why?
|
| Hospitals, Special | 1 | 2013 | 89 | 0.100 |
Why?
|
| Chromosomes, Human | 1 | 1995 | 437 | 0.100 |
Why?
|
| Adenine Nucleotide Translocator 2 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Hydrops Fetalis | 1 | 2013 | 113 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2006 | 567 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 388 | 0.100 |
Why?
|
| Term Birth | 1 | 2013 | 140 | 0.100 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 12536 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2021 | 3813 | 0.100 |
Why?
|
| Antioxidants | 1 | 2020 | 1674 | 0.100 |
Why?
|
| Cell Death | 2 | 2015 | 1679 | 0.100 |
Why?
|
| Sphingolipids | 1 | 2013 | 178 | 0.100 |
Why?
|
| DNA, Viral | 1 | 2019 | 2201 | 0.100 |
Why?
|
| Diseases in Twins | 1 | 1994 | 447 | 0.100 |
Why?
|
| Pelvic Neoplasms | 2 | 2020 | 250 | 0.100 |
Why?
|
| Osteopontin | 5 | 2006 | 306 | 0.100 |
Why?
|
| Vitamins | 1 | 2020 | 1638 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 4414 | 0.100 |
Why?
|
| Gene Deletion | 7 | 2004 | 2673 | 0.100 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 146 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2012 | 118 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2018 | 1572 | 0.100 |
Why?
|
| Angiopoietin-1 | 1 | 2012 | 133 | 0.100 |
Why?
|
| In Situ Hybridization | 3 | 2010 | 1892 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2008 | 1801 | 0.090 |
Why?
|
| Clostridium perfringens | 2 | 2010 | 29 | 0.090 |
Why?
|
| Massachusetts | 5 | 2018 | 8888 | 0.090 |
Why?
|
| Pandemics | 2 | 2022 | 8748 | 0.090 |
Why?
|
| Cadherins | 1 | 2016 | 904 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2007 | 386 | 0.090 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 222 | 0.090 |
Why?
|
| Cell Division | 9 | 2001 | 4473 | 0.090 |
Why?
|
| Molecular Sequence Data | 13 | 2006 | 17617 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2016 | 1336 | 0.090 |
Why?
|
| Epithelium | 7 | 2008 | 1607 | 0.090 |
Why?
|
| Alleles | 13 | 2005 | 6894 | 0.090 |
Why?
|
| Colposcopy | 2 | 2021 | 151 | 0.090 |
Why?
|
| Versicans | 1 | 2010 | 40 | 0.090 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 6 | 2001 | 325 | 0.090 |
Why?
|
| Postpartum Period | 1 | 1998 | 1198 | 0.090 |
Why?
|
| Cystadenocarcinoma | 5 | 1994 | 54 | 0.090 |
Why?
|
| New Hampshire | 1 | 2010 | 174 | 0.090 |
Why?
|
| Genes, BRCA2 | 1 | 2013 | 593 | 0.090 |
Why?
|
| Survivors | 3 | 2007 | 2381 | 0.090 |
Why?
|
| Cell Count | 2 | 2010 | 1831 | 0.090 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2011 | 111 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2018 | 2766 | 0.080 |
Why?
|
| Mutation | 16 | 2018 | 30211 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1992 | 1353 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2018 | 2574 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2019 | 1546 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 20757 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 547 | 0.080 |
Why?
|
| Menopause | 2 | 1994 | 1656 | 0.080 |
Why?
|
| Blood Transfusion | 1 | 2016 | 1308 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 1105 | 0.080 |
Why?
|
| Biological Factors | 1 | 1990 | 155 | 0.080 |
Why?
|
| DNA Repair | 1 | 2018 | 2050 | 0.080 |
Why?
|
| Gene Dosage | 3 | 2016 | 1211 | 0.080 |
Why?
|
| Appendiceal Neoplasms | 2 | 2005 | 155 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2020 | 3140 | 0.080 |
Why?
|
| Recurrence | 7 | 2019 | 8507 | 0.080 |
Why?
|
| Anesthetics | 1 | 2014 | 525 | 0.080 |
Why?
|
| Cytokines | 5 | 1998 | 7450 | 0.080 |
Why?
|
| Germ-Line Mutation | 3 | 2013 | 1883 | 0.080 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 117 | 0.080 |
Why?
|
| Gene Amplification | 5 | 2007 | 1088 | 0.080 |
Why?
|
| Granulosa Cell Tumor | 1 | 2009 | 76 | 0.080 |
Why?
|
| Contractile Proteins | 1 | 2009 | 240 | 0.080 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 130 | 0.080 |
Why?
|
| Core Binding Factor Alpha 3 Subunit | 1 | 2008 | 58 | 0.080 |
Why?
|
| Infusions, Parenteral | 2 | 2021 | 395 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 560 | 0.080 |
Why?
|
| Karyotyping | 5 | 1995 | 1176 | 0.080 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 392 | 0.080 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 622 | 0.080 |
Why?
|
| Fetal Diseases | 1 | 1994 | 916 | 0.080 |
Why?
|
| Tight Junctions | 2 | 2010 | 324 | 0.080 |
Why?
|
| Child | 7 | 2018 | 80906 | 0.080 |
Why?
|
| Autoantibodies | 2 | 2010 | 2117 | 0.080 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2007 | 1305 | 0.070 |
Why?
|
| Genomic Instability | 1 | 2012 | 716 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 2783 | 0.070 |
Why?
|
| Ultrasonography | 6 | 1997 | 6004 | 0.070 |
Why?
|
| Embryo Implantation | 2 | 1996 | 272 | 0.070 |
Why?
|
| Cell Movement | 3 | 2016 | 5209 | 0.070 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 1990 | 498 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2012 | 751 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 2884 | 0.070 |
Why?
|
| Transfection | 5 | 2015 | 5757 | 0.070 |
Why?
|
| Lymphokines | 2 | 1988 | 924 | 0.070 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2007 | 53 | 0.070 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1988 | 510 | 0.070 |
Why?
|
| Salmon | 1 | 2007 | 34 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 5 | 2001 | 1698 | 0.070 |
Why?
|
| Proteins | 3 | 1999 | 6009 | 0.070 |
Why?
|
| Talc | 1 | 2007 | 48 | 0.070 |
Why?
|
| Up-Regulation | 8 | 2010 | 4146 | 0.070 |
Why?
|
| Postmenopause | 2 | 2004 | 2518 | 0.070 |
Why?
|
| Dissection | 3 | 2003 | 299 | 0.070 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 809 | 0.070 |
Why?
|
| Risk Assessment | 7 | 2021 | 24314 | 0.070 |
Why?
|
| Hydatidiform Mole, Invasive | 3 | 1998 | 4 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2014 | 1610 | 0.070 |
Why?
|
| X Chromosome | 4 | 1998 | 819 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2016 | 1150 | 0.070 |
Why?
|
| Deoxycytidine | 2 | 2018 | 887 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1946 | 0.070 |
Why?
|
| Base Sequence | 9 | 2000 | 12418 | 0.070 |
Why?
|
| Selenium-Binding Proteins | 1 | 2006 | 18 | 0.070 |
Why?
|
| Eosinophil-Derived Neurotoxin | 1 | 2006 | 13 | 0.070 |
Why?
|
| Myometrium | 1 | 2007 | 174 | 0.070 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 979 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 1986 | 863 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2022 | 54924 | 0.070 |
Why?
|
| Decidua | 2 | 2022 | 82 | 0.070 |
Why?
|
| Radioimmunoassay | 6 | 1994 | 863 | 0.070 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 4114 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2000 | 2748 | 0.060 |
Why?
|
| Hong Kong | 2 | 2017 | 170 | 0.060 |
Why?
|
| Granzymes | 1 | 2007 | 277 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2022 | 26420 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2003 | 2936 | 0.060 |
Why?
|
| Heterozygote | 6 | 2005 | 2798 | 0.060 |
Why?
|
| Cell Survival | 6 | 2016 | 5772 | 0.060 |
Why?
|
| United States | 6 | 2021 | 73027 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 2 | 2012 | 1351 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2018 | 2517 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1992 | 1854 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 1883 | 0.060 |
Why?
|
| Cytoplasm | 4 | 2008 | 1505 | 0.060 |
Why?
|
| Lymph Nodes | 4 | 2007 | 3472 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2020 | 7876 | 0.060 |
Why?
|
| Lasers | 3 | 2004 | 952 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 1997 | 310 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2010 | 2256 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2015 | 1788 | 0.060 |
Why?
|
| Immune Sera | 2 | 1983 | 605 | 0.060 |
Why?
|
| Histocompatibility Antigens | 1 | 1986 | 479 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2006 | 2800 | 0.060 |
Why?
|
| Signal Transduction | 5 | 2015 | 23642 | 0.060 |
Why?
|
| Cystadenocarcinoma, Mucinous | 2 | 2005 | 51 | 0.060 |
Why?
|
| Peptide Fragments | 6 | 2007 | 5151 | 0.060 |
Why?
|
| Mucin-1 | 2 | 2009 | 537 | 0.060 |
Why?
|
| BRCA2 Protein | 2 | 2007 | 802 | 0.060 |
Why?
|
| Premature Birth | 1 | 2017 | 1829 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 1996 | 322 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 547 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2008 | 3114 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2021 | 5314 | 0.060 |
Why?
|
| Glycolipids | 1 | 1985 | 205 | 0.060 |
Why?
|
| Co-Repressor Proteins | 2 | 2016 | 190 | 0.060 |
Why?
|
| Pregnadienediols | 1 | 2003 | 9 | 0.060 |
Why?
|
| Amino Acid Sequence | 6 | 2006 | 13420 | 0.060 |
Why?
|
| Blotting, Northern | 3 | 1994 | 1550 | 0.060 |
Why?
|
| Vagina | 3 | 2015 | 850 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1273 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 11930 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2007 | 563 | 0.050 |
Why?
|
| Cell Adhesion | 3 | 2016 | 3096 | 0.050 |
Why?
|
| Body Mass Index | 4 | 2016 | 13053 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2055 | 0.050 |
Why?
|
| Quality of Life | 6 | 2005 | 13489 | 0.050 |
Why?
|
| Anemia | 2 | 2012 | 1514 | 0.050 |
Why?
|
| Developing Countries | 1 | 2016 | 2913 | 0.050 |
Why?
|
| Population Surveillance | 1 | 1994 | 2594 | 0.050 |
Why?
|
| Cyclin E | 1 | 2004 | 155 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2005 | 631 | 0.050 |
Why?
|
| Y Chromosome | 2 | 1995 | 205 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 627 | 0.050 |
Why?
|
| Micromanipulation | 1 | 2003 | 53 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 1805 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 928 | 0.050 |
Why?
|
| Kallikreins | 1 | 2004 | 219 | 0.050 |
Why?
|
| Intraoperative Complications | 3 | 2007 | 1171 | 0.050 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 1269 | 0.050 |
Why?
|
| Mass Screening | 2 | 2001 | 5458 | 0.050 |
Why?
|
| Marriage | 4 | 2003 | 351 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2005 | 684 | 0.050 |
Why?
|
| Family Therapy | 5 | 1990 | 214 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 3609 | 0.050 |
Why?
|
| Microsatellite Repeats | 6 | 2001 | 784 | 0.050 |
Why?
|
| Transcription Factors | 5 | 2002 | 12165 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2016 | 3800 | 0.050 |
Why?
|
| Abortion, Missed | 3 | 1994 | 11 | 0.050 |
Why?
|
| Budesonide | 1 | 2003 | 162 | 0.050 |
Why?
|
| Point Mutation | 2 | 2000 | 1594 | 0.050 |
Why?
|
| Lymphatic Metastasis | 5 | 2015 | 2908 | 0.050 |
Why?
|
| Haptoglobins | 1 | 2003 | 165 | 0.050 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2002 | 99 | 0.050 |
Why?
|
| Survival Analysis | 7 | 2012 | 10098 | 0.050 |
Why?
|
| Propionibacterium acnes | 2 | 1983 | 59 | 0.050 |
Why?
|
| Leukocytes | 1 | 1990 | 2035 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3228 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2009 | 2201 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2013 | 4035 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2015 | 3476 | 0.050 |
Why?
|
| Cholecalciferol | 1 | 2007 | 557 | 0.050 |
Why?
|
| Dissociative Disorders | 2 | 1994 | 235 | 0.050 |
Why?
|
| Polyploidy | 1 | 2002 | 120 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2009 | 4351 | 0.050 |
Why?
|
| DNA Methylation | 4 | 2017 | 4426 | 0.050 |
Why?
|
| Animals | 19 | 2022 | 169222 | 0.050 |
Why?
|
| Piperazines | 2 | 2013 | 2552 | 0.050 |
Why?
|
| Blotting, Western | 5 | 2010 | 5024 | 0.050 |
Why?
|
| Spermatozoa | 1 | 1985 | 632 | 0.050 |
Why?
|
| CHO Cells | 2 | 2010 | 1379 | 0.050 |
Why?
|
| Turner Syndrome | 1 | 1982 | 130 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 2004 | 0.050 |
Why?
|
| Cell Differentiation | 3 | 2014 | 11665 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2013 | 2341 | 0.050 |
Why?
|
| Flow Cytometry | 6 | 2010 | 5902 | 0.050 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2000 | 228 | 0.050 |
Why?
|
| Genital Diseases, Female | 2 | 2001 | 192 | 0.050 |
Why?
|
| Cystadenoma | 2 | 2000 | 77 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 777 | 0.050 |
Why?
|
| Abortion, Incomplete | 2 | 1994 | 13 | 0.050 |
Why?
|
| Puerperal Disorders | 1 | 1984 | 304 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 4648 | 0.040 |
Why?
|
| Estradiol | 5 | 1994 | 1951 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 36534 | 0.040 |
Why?
|
| Mice | 12 | 2022 | 82024 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2002 | 251 | 0.040 |
Why?
|
| Protein Biosynthesis | 4 | 2006 | 2094 | 0.040 |
Why?
|
| Liver Neoplasms | 3 | 2011 | 4362 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2020 | 148 | 0.040 |
Why?
|
| Psychotherapy, Group | 3 | 1990 | 417 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1625 | 0.040 |
Why?
|
| Human Genome Project | 1 | 2000 | 202 | 0.040 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 1999 | 21 | 0.040 |
Why?
|
| Electrocoagulation | 1 | 2020 | 156 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 3834 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 5798 | 0.040 |
Why?
|
| Selenoproteins | 1 | 2021 | 216 | 0.040 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 40 | 0.040 |
Why?
|
| Cardiac Output, Low | 1 | 2000 | 192 | 0.040 |
Why?
|
| Indoles | 1 | 2007 | 1835 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2007 | 5505 | 0.040 |
Why?
|
| Observer Variation | 3 | 2019 | 2618 | 0.040 |
Why?
|
| Receptor, erbB-3 | 1 | 2000 | 142 | 0.040 |
Why?
|
| Cells, Cultured | 8 | 2010 | 19017 | 0.040 |
Why?
|
| Information Services | 1 | 2000 | 239 | 0.040 |
Why?
|
| Cytogenetics | 2 | 1992 | 198 | 0.040 |
Why?
|
| Suction | 1 | 2020 | 268 | 0.040 |
Why?
|
| RecQ Helicases | 1 | 1999 | 53 | 0.040 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2019 | 110 | 0.040 |
Why?
|
| Topotecan | 3 | 2004 | 131 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1605 | 0.040 |
Why?
|
| RNA, Untranslated | 1 | 2002 | 455 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2010 | 381 | 0.040 |
Why?
|
| Infertility, Female | 1 | 2005 | 763 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2013 | 3288 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2009 | 7445 | 0.040 |
Why?
|
| Chickens | 1 | 2020 | 845 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 1993 | 3159 | 0.040 |
Why?
|
| Uterine Perforation | 1 | 2018 | 4 | 0.040 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2003 | 572 | 0.040 |
Why?
|
| Omentum | 1 | 2019 | 168 | 0.040 |
Why?
|
| Biological Products | 1 | 1988 | 948 | 0.040 |
Why?
|
| Online Systems | 1 | 2019 | 182 | 0.040 |
Why?
|
| Human papillomavirus 18 | 1 | 2019 | 125 | 0.040 |
Why?
|
| Carotenoids | 2 | 1995 | 620 | 0.040 |
Why?
|
| Genetic Complementation Test | 1 | 1999 | 557 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 564 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2006 | 505 | 0.040 |
Why?
|
| Cytarabine | 1 | 2020 | 695 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 5366 | 0.040 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1998 | 94 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2012 | 3620 | 0.040 |
Why?
|
| Spinal Puncture | 1 | 2000 | 286 | 0.040 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 1753 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1982 | 0.040 |
Why?
|
| Adaptation, Psychological | 2 | 2007 | 2663 | 0.040 |
Why?
|
| RNA Interference | 2 | 2017 | 2830 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 1321 | 0.040 |
Why?
|
| Male | 24 | 2023 | 364641 | 0.040 |
Why?
|
| Drug Therapy, Combination | 6 | 1984 | 6314 | 0.040 |
Why?
|
| Genome | 1 | 2005 | 1754 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2002 | 617 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1997 | 781 | 0.040 |
Why?
|
| Radiography | 2 | 2007 | 6983 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2006 | 9666 | 0.040 |
Why?
|
| Saudi Arabia | 1 | 1998 | 212 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2003 | 788 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 1978 | 105 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 268 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 6973 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2002 | 812 | 0.030 |
Why?
|
| Immunophenotyping | 2 | 2013 | 1863 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2000 | 633 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1998 | 378 | 0.030 |
Why?
|
| Fenfluramine | 1 | 1996 | 58 | 0.030 |
Why?
|
| Contraception | 2 | 1995 | 362 | 0.030 |
Why?
|
| Patient Compliance | 3 | 2004 | 2697 | 0.030 |
Why?
|
| Organ Specificity | 2 | 2017 | 1968 | 0.030 |
Why?
|
| Phenotype | 4 | 2018 | 16723 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2020 | 1642 | 0.030 |
Why?
|
| Vulva | 2 | 2008 | 85 | 0.030 |
Why?
|
| Postpartum Hemorrhage | 1 | 1980 | 275 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 1027 | 0.030 |
Why?
|
| Postoperative Complications | 5 | 2021 | 15831 | 0.030 |
Why?
|
| Diet | 3 | 2007 | 8087 | 0.030 |
Why?
|
| Appetite Depressants | 1 | 1996 | 108 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 794 | 0.030 |
Why?
|
| Dietary Proteins | 2 | 1995 | 960 | 0.030 |
Why?
|
| Cell Line, Transformed | 2 | 2013 | 866 | 0.030 |
Why?
|
| Exons | 3 | 2000 | 2393 | 0.030 |
Why?
|
| DNA Probes | 3 | 2010 | 542 | 0.030 |
Why?
|
| Twins | 2 | 1995 | 341 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1997 | 411 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2010 | 610 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2019 | 468 | 0.030 |
Why?
|
| Pelvis | 1 | 1980 | 736 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1998 | 361 | 0.030 |
Why?
|
| Lymphoma | 1 | 2005 | 1897 | 0.030 |
Why?
|
| Cyclins | 1 | 1998 | 605 | 0.030 |
Why?
|
| DNA Copy Number Variations | 2 | 2016 | 2048 | 0.030 |
Why?
|
| Histones | 1 | 2006 | 2600 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 18062 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 124 | 0.030 |
Why?
|
| Robotics | 2 | 2015 | 813 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 3726 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1985 | 2819 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 1667 | 0.030 |
Why?
|
| Transglutaminases | 1 | 2016 | 200 | 0.030 |
Why?
|
| Demography | 1 | 2020 | 1641 | 0.030 |
Why?
|
| Centromere | 1 | 1996 | 214 | 0.030 |
Why?
|
| Receptors, Androgen | 2 | 1998 | 1089 | 0.030 |
Why?
|
| Glycosylation | 2 | 2010 | 1100 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2013 | 2932 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1999 | 1228 | 0.030 |
Why?
|
| Sexual Behavior | 4 | 2005 | 2197 | 0.030 |
Why?
|
| Etanidazole | 1 | 1994 | 22 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1999 | 2299 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2021 | 3074 | 0.030 |
Why?
|
| Intermediate Filaments | 1 | 1995 | 171 | 0.030 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 1994 | 21 | 0.030 |
Why?
|
| Abortion, Therapeutic | 1 | 1994 | 35 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 1998 | 671 | 0.030 |
Why?
|
| Thecoma | 1 | 1994 | 11 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 1985 | 816 | 0.030 |
Why?
|
| Menstruation Disturbances | 1 | 1995 | 143 | 0.030 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 1994 | 14 | 0.030 |
Why?
|
| Lactosylceramides | 1 | 2013 | 15 | 0.030 |
Why?
|
| Jews | 1 | 1996 | 359 | 0.030 |
Why?
|
| Bulimia | 1 | 1996 | 405 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 1996 | 392 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2002 | 4030 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1994 | 134 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2000 | 1752 | 0.030 |
Why?
|
| Length of Stay | 2 | 2021 | 6495 | 0.030 |
Why?
|
| Triage | 1 | 2021 | 996 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1995 | 377 | 0.030 |
Why?
|
| DNA Fingerprinting | 1 | 1994 | 114 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2003 | 1804 | 0.030 |
Why?
|
| Agranulocytosis | 2 | 1984 | 98 | 0.030 |
Why?
|
| Taxoids | 2 | 2012 | 665 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1994 | 155 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 530 | 0.030 |
Why?
|
| Blotting, Southern | 3 | 2004 | 775 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 534 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 1880 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1997 | 1034 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1978 | 1622 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1992 | 42 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1995 | 457 | 0.030 |
Why?
|
| Polymorphism, Genetic | 3 | 2002 | 4248 | 0.030 |
Why?
|
| Genes, myc | 1 | 1994 | 391 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1994 | 386 | 0.030 |
Why?
|
| Social Support | 4 | 2005 | 2193 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1995 | 640 | 0.030 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 2 | 1989 | 95 | 0.030 |
Why?
|
| Pyrazines | 1 | 2018 | 1205 | 0.030 |
Why?
|
| Family Health | 2 | 2009 | 1255 | 0.030 |
Why?
|
| Clinical Enzyme Tests | 1 | 2012 | 114 | 0.030 |
Why?
|
| Caffeine | 1 | 1997 | 703 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2007 | 6339 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1998 | 998 | 0.020 |
Why?
|
| Chromosome Mapping | 5 | 2000 | 4618 | 0.020 |
Why?
|
| Molecular Probes | 1 | 1994 | 309 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 948 | 0.020 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 123 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 1998 | 2923 | 0.020 |
Why?
|
| Proteomics | 2 | 2022 | 3912 | 0.020 |
Why?
|
| Biopsy | 3 | 2008 | 6786 | 0.020 |
Why?
|
| Transcription, Genetic | 4 | 2004 | 7612 | 0.020 |
Why?
|
| Progesterone | 2 | 1994 | 752 | 0.020 |
Why?
|
| Cricetinae | 2 | 2010 | 2423 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 756 | 0.020 |
Why?
|
| Somatoform Disorders | 1 | 1994 | 425 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2016 | 1652 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2013 | 355 | 0.020 |
Why?
|
| DNA Replication | 1 | 2018 | 1427 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 766 | 0.020 |
Why?
|
| Dosage Compensation, Genetic | 3 | 1998 | 209 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 428 | 0.020 |
Why?
|
| Specialization | 1 | 2016 | 779 | 0.020 |
Why?
|
| Codon | 1 | 1993 | 599 | 0.020 |
Why?
|
| DNA Damage | 2 | 2012 | 2470 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 1994 | 393 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1904 | 0.020 |
Why?
|
| Receptor, erbB-2 | 2 | 2001 | 2601 | 0.020 |
Why?
|
| Genotype | 1 | 2005 | 13042 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2019 | 1043 | 0.020 |
Why?
|
| Schizophrenia | 5 | 1990 | 6983 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 1998 | 2906 | 0.020 |
Why?
|
| Splenectomy | 1 | 1992 | 392 | 0.020 |
Why?
|
| Fluoxetine | 1 | 1994 | 733 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1104 | 0.020 |
Why?
|
| Methionine | 1 | 2013 | 573 | 0.020 |
Why?
|
| Stress, Psychological | 5 | 2004 | 4530 | 0.020 |
Why?
|
| Neoplasms | 3 | 2015 | 22365 | 0.020 |
Why?
|
| Personality Inventory | 3 | 2005 | 1018 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 331 | 0.020 |
Why?
|
| Immune Tolerance | 2 | 1992 | 2322 | 0.020 |
Why?
|
| Phthalazines | 1 | 2013 | 397 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 6668 | 0.020 |
Why?
|
| Thrombocytopenia | 3 | 2000 | 1179 | 0.020 |
Why?
|
| Home Nursing | 1 | 1990 | 92 | 0.020 |
Why?
|
| Triplets | 1 | 1990 | 42 | 0.020 |
Why?
|
| Office Visits | 1 | 1994 | 595 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 3740 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 1995 | 1207 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 686 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 1993 | 546 | 0.020 |
Why?
|
| Vaccination | 1 | 2002 | 3437 | 0.020 |
Why?
|
| Intestines | 1 | 2019 | 1909 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2010 | 170 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 270 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 275 | 0.020 |
Why?
|
| Viral Load | 1 | 2019 | 3396 | 0.020 |
Why?
|
| Gravitation | 1 | 2009 | 82 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 1838 | 0.020 |
Why?
|
| Estrogens | 3 | 2002 | 1536 | 0.020 |
Why?
|
| Melanoma | 1 | 2008 | 5706 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 2889 | 0.020 |
Why?
|
| Antibody Formation | 2 | 1984 | 1392 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 2634 | 0.020 |
Why?
|
| Reference Values | 2 | 2000 | 4938 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 812 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1998 | 3657 | 0.020 |
Why?
|
| Obstetric Labor, Premature | 1 | 1990 | 268 | 0.020 |
Why?
|
| Monokines | 1 | 1988 | 71 | 0.020 |
Why?
|
| Folic Acid | 1 | 2015 | 1337 | 0.020 |
Why?
|
| Receptors, Laminin | 1 | 2007 | 26 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 18344 | 0.020 |
Why?
|
| Concanavalin A | 1 | 1988 | 190 | 0.020 |
Why?
|
| Fee-for-Service Plans | 1 | 2013 | 713 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2680 | 0.020 |
Why?
|
| Electron Probe Microanalysis | 1 | 2007 | 32 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2018 | 2028 | 0.020 |
Why?
|
| Somatomedins | 1 | 1988 | 179 | 0.020 |
Why?
|
| Aftercare | 1 | 1994 | 916 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2008 | 737 | 0.020 |
Why?
|
| Clinical Trials as Topic | 4 | 2000 | 8052 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 6515 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1988 | 218 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2450 | 0.020 |
Why?
|
| Abdomen | 1 | 2013 | 1137 | 0.020 |
Why?
|
| Microscopy, Polarization | 1 | 2007 | 88 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 687 | 0.020 |
Why?
|
| Vinblastine | 2 | 1989 | 487 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1995 | 1996 | 0.020 |
Why?
|
| Life Change Events | 4 | 1994 | 960 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2006 | 27 | 0.020 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2007 | 194 | 0.020 |
Why?
|
| Sarcoma | 1 | 1978 | 1804 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2001 | 1826 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2012 | 1666 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2008 | 472 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 2 | 1983 | 91 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 2916 | 0.020 |
Why?
|
| Emotions | 4 | 2003 | 2766 | 0.020 |
Why?
|
| Family | 3 | 1990 | 3210 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2021 | 3855 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1992 | 1418 | 0.020 |
Why?
|
| Research Design | 1 | 2022 | 6211 | 0.020 |
Why?
|
| Proteome | 2 | 2006 | 1890 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 1534 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 283 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1988 | 828 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 10757 | 0.020 |
Why?
|
| Corynebacterium | 1 | 1985 | 49 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2013 | 2149 | 0.020 |
Why?
|
| Autophagy | 1 | 2013 | 1349 | 0.020 |
Why?
|
| Schizophrenic Psychology | 2 | 1990 | 1649 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 1985 | 306 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2007 | 304 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 2627 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 943 | 0.020 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2005 | 7 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 2007 | 369 | 0.020 |
Why?
|
| Binding Sites, Antibody | 1 | 1985 | 340 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 1994 | 1240 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1193 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2000 | 4978 | 0.020 |
Why?
|
| Amniocentesis | 1 | 1985 | 116 | 0.010 |
Why?
|
| Infant Mortality | 1 | 1990 | 752 | 0.010 |
Why?
|
| Filgrastim | 1 | 2005 | 131 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 317 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 2007 | 662 | 0.010 |
Why?
|
| Groin | 1 | 1985 | 106 | 0.010 |
Why?
|
| Microdissection | 1 | 2004 | 150 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 20218 | 0.010 |
Why?
|
| Asthma | 1 | 2003 | 6273 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2009 | 729 | 0.010 |
Why?
|
| Breast Neoplasms | 4 | 2007 | 21206 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2013 | 4289 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 1319 | 0.010 |
Why?
|
| HLA-C Antigens | 1 | 1984 | 146 | 0.010 |
Why?
|
| Microvilli | 1 | 1984 | 235 | 0.010 |
Why?
|
| HLA-A Antigens | 1 | 1984 | 223 | 0.010 |
Why?
|
| Liver | 3 | 1990 | 7574 | 0.010 |
Why?
|
| Decision Trees | 1 | 2006 | 508 | 0.010 |
Why?
|
| Interferons | 1 | 1988 | 720 | 0.010 |
Why?
|
| Drug Costs | 1 | 2012 | 1195 | 0.010 |
Why?
|
| Sequence Deletion | 2 | 2000 | 1494 | 0.010 |
Why?
|
| Data Collection | 1 | 2013 | 3326 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1988 | 1156 | 0.010 |
Why?
|
| Neutropenia | 2 | 2000 | 892 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1985 | 699 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2005 | 453 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2008 | 1080 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 639 | 0.010 |
Why?
|
| Boston | 3 | 2005 | 9368 | 0.010 |
Why?
|
| Gonadotropins | 2 | 1982 | 241 | 0.010 |
Why?
|
| Double-Blind Method | 4 | 2003 | 12464 | 0.010 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 1188 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2002 | 2510 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1984 | 642 | 0.010 |
Why?
|
| Selenium | 1 | 2006 | 418 | 0.010 |
Why?
|
| Ovarian Diseases | 1 | 2004 | 136 | 0.010 |
Why?
|
| Receptors, Transferrin | 1 | 1985 | 300 | 0.010 |
Why?
|
| HLA-B Antigens | 1 | 1984 | 330 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 1993 | 2008 | 0.010 |
Why?
|
| Attitude to Health | 3 | 2003 | 2024 | 0.010 |
Why?
|
| Reproduction | 2 | 2005 | 646 | 0.010 |
Why?
|
| Macrophages | 1 | 1998 | 5799 | 0.010 |
Why?
|
| Genetic Techniques | 1 | 2005 | 427 | 0.010 |
Why?
|
| Interleukins | 1 | 1988 | 796 | 0.010 |
Why?
|
| Chromosome Painting | 1 | 2002 | 26 | 0.010 |
Why?
|
| Transplantation, Homologous | 2 | 1984 | 4833 | 0.010 |
Why?
|
| Sexuality | 1 | 2004 | 179 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2005 | 563 | 0.010 |
Why?
|
| Genomic Imprinting | 1 | 2004 | 326 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 1656 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1995 | 4937 | 0.010 |
Why?
|
| Biotin | 1 | 2003 | 256 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 1994 | 4640 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2008 | 1505 | 0.010 |
Why?
|
| Peritoneum | 2 | 1998 | 227 | 0.010 |
Why?
|
| Genome, Human | 2 | 2005 | 4443 | 0.010 |
Why?
|
| Histological Techniques | 1 | 2002 | 193 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 1984 | 408 | 0.010 |
Why?
|
| Dimerization | 1 | 2003 | 887 | 0.010 |
Why?
|
| Child Abuse, Sexual | 2 | 1994 | 400 | 0.010 |
Why?
|
| Age Distribution | 1 | 2007 | 2871 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 464 | 0.010 |
Why?
|
| Mitochondria | 1 | 2015 | 3681 | 0.010 |
Why?
|
| Polyadenylation | 1 | 2002 | 114 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 10627 | 0.010 |
Why?
|
| Placebos | 2 | 1996 | 1667 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1983 | 1065 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2003 | 399 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1985 | 1617 | 0.010 |
Why?
|
| Hyperemesis Gravidarum | 1 | 1981 | 24 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2016 | 14486 | 0.010 |
Why?
|
| Child Abuse | 3 | 1994 | 1091 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2014 | 3589 | 0.010 |
Why?
|
| Risk Reduction Behavior | 1 | 2007 | 1119 | 0.010 |
Why?
|
| Complement C3 | 1 | 1982 | 434 | 0.010 |
Why?
|
| Smoking | 2 | 2010 | 9089 | 0.010 |
Why?
|
| Pregnancy Complications | 2 | 1987 | 2972 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1988 | 1942 | 0.010 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 1980 | 56 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 1892 | 0.010 |
Why?
|
| Hospitalization | 3 | 1998 | 10840 | 0.010 |
Why?
|
| Contraceptive Agents, Female | 1 | 1981 | 123 | 0.010 |
Why?
|
| Psychology | 1 | 2002 | 353 | 0.010 |
Why?
|
| Computer Systems | 1 | 2001 | 469 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9343 | 0.010 |
Why?
|
| Vaginal Diseases | 1 | 1981 | 103 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 1994 | 6029 | 0.010 |
Why?
|
| Femoral Vein | 1 | 2000 | 156 | 0.010 |
Why?
|
| Spirituality | 1 | 2004 | 430 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 3428 | 0.010 |
Why?
|
| WT1 Proteins | 1 | 2000 | 183 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2006 | 2731 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 1419 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 1998 | 92 | 0.010 |
Why?
|
| Palliative Care | 1 | 1994 | 3642 | 0.010 |
Why?
|
| Iliac Artery | 1 | 1980 | 344 | 0.010 |
Why?
|
| Androgens | 1 | 2006 | 1281 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1979 | 571 | 0.010 |
Why?
|
| Immunity | 1 | 1984 | 1003 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 2003 | 1695 | 0.010 |
Why?
|
| Kinetics | 2 | 2001 | 6328 | 0.010 |
Why?
|
| Vasculitis | 1 | 1982 | 525 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2000 | 389 | 0.010 |
Why?
|
| Mesna | 1 | 1998 | 62 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2003 | 1831 | 0.010 |
Why?
|
| Estrone | 1 | 1979 | 234 | 0.010 |
Why?
|
| Physicians | 1 | 2016 | 4598 | 0.010 |
Why?
|
| Severity of Illness Index | 2 | 1994 | 15944 | 0.010 |
Why?
|
| Systole | 1 | 2000 | 937 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1982 | 1527 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1985 | 2001 | 0.010 |
Why?
|
| Ifosfamide | 1 | 1998 | 233 | 0.010 |
Why?
|
| Epitopes | 1 | 1984 | 2526 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1997 | 67 | 0.010 |
Why?
|
| Neurofibromin 1 | 1 | 1999 | 190 | 0.010 |
Why?
|
| Trinucleotide Repeats | 1 | 1998 | 257 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 790 | 0.010 |
Why?
|
| Counseling | 1 | 2005 | 1554 | 0.010 |
Why?
|
| Rabbits | 1 | 1983 | 4771 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1977 | 636 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 1979 | 505 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 892 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 1980 | 450 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1988 | 3329 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5394 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1977 | 915 | 0.010 |
Why?
|
| Laparotomy | 1 | 1998 | 459 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2003 | 2202 | 0.010 |
Why?
|
| Sex Determination Analysis | 1 | 1995 | 46 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1998 | 565 | 0.010 |
Why?
|
| Formaldehyde | 1 | 1977 | 362 | 0.010 |
Why?
|
| Tretinoin | 1 | 1999 | 524 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 4063 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2863 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 12795 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1979 | 498 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 2230 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 1995 | 121 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1996 | 313 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1244 | 0.010 |
Why?
|
| Arteries | 1 | 1980 | 1127 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1977 | 619 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2002 | 1280 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1997 | 719 | 0.010 |
Why?
|
| Clone Cells | 1 | 1998 | 1669 | 0.010 |
Why?
|
| Chlorambucil | 1 | 1994 | 42 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1983 | 6231 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 1995 | 224 | 0.010 |
Why?
|
| Self Concept | 1 | 1980 | 1043 | 0.010 |
Why?
|
| Health Surveys | 1 | 2004 | 4056 | 0.010 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 1994 | 139 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1715 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 7851 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1977 | 2014 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1993 | 6875 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1985 | 3205 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1979 | 1480 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 16041 | 0.010 |
Why?
|
| RNA | 1 | 2002 | 2718 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 1994 | 395 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 5884 | 0.010 |
Why?
|
| Receptors, Interferon | 1 | 1992 | 115 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1977 | 1230 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2000 | 1760 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1991 | 261 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2827 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1984 | 2173 | 0.010 |
Why?
|
| Genomics | 1 | 2008 | 5925 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 7213 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 1793 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 8740 | 0.010 |
Why?
|
| Peptides | 1 | 2003 | 4354 | 0.010 |
Why?
|
| Salpingostomy | 1 | 1990 | 8 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1994 | 1647 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 1142 | 0.010 |
Why?
|
| Thiazoles | 1 | 1998 | 1542 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1990 | 2000 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1994 | 344 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1982 | 4564 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 2 | 1986 | 727 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 1984 | 3081 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1990 | 63 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1993 | 1252 | 0.010 |
Why?
|
| Anxiety | 1 | 2005 | 4672 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2000 | 4194 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1980 | 2935 | 0.010 |
Why?
|
| Pain | 1 | 2004 | 5100 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1991 | 414 | 0.010 |
Why?
|
| Comorbidity | 2 | 1994 | 10590 | 0.000 |
Why?
|
| Luteinizing Hormone | 2 | 1982 | 822 | 0.000 |
Why?
|
| Granulocytes | 1 | 1991 | 551 | 0.000 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 1988 | 40 | 0.000 |
Why?
|
| Meningeal Neoplasms | 1 | 1978 | 1253 | 0.000 |
Why?
|
| Receptors, Somatomedin | 1 | 1988 | 57 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1981 | 3467 | 0.000 |
Why?
|
| Oxygen | 1 | 2000 | 4269 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1991 | 1625 | 0.000 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 1988 | 57 | 0.000 |
Why?
|
| Platelet Count | 1 | 1991 | 787 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1988 | 455 | 0.000 |
Why?
|
| Heart | 1 | 2000 | 4444 | 0.000 |
Why?
|
| Prevalence | 2 | 1994 | 15867 | 0.000 |
Why?
|
| Placental Lactogen | 1 | 1986 | 17 | 0.000 |
Why?
|
| Monitoring, Physiologic | 2 | 1985 | 1798 | 0.000 |
Why?
|
| Interpersonal Relations | 2 | 1985 | 1434 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1993 | 1248 | 0.000 |
Why?
|
| Affect | 1 | 1994 | 1495 | 0.000 |
Why?
|
| Health Services Needs and Demand | 1 | 1994 | 1406 | 0.000 |
Why?
|
| Dyspnea | 1 | 1994 | 1352 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2540 | 0.000 |
Why?
|
| Education | 1 | 1989 | 533 | 0.000 |
Why?
|
| Obesity, Morbid | 1 | 1996 | 1298 | 0.000 |
Why?
|
| Mood Disorders | 1 | 1992 | 1129 | 0.000 |
Why?
|
| Chronic Disease | 1 | 2000 | 9384 | 0.000 |
Why?
|
| Flupenthixol | 1 | 1984 | 11 | 0.000 |
Why?
|
| Fluphenazine | 1 | 1984 | 35 | 0.000 |
Why?
|
| Paternity | 1 | 1984 | 14 | 0.000 |
Why?
|
| Monocytes | 1 | 1994 | 2605 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1988 | 839 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1985 | 491 | 0.000 |
Why?
|
| Prolactin | 1 | 1986 | 627 | 0.000 |
Why?
|
| Reoperation | 1 | 1994 | 4329 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1992 | 6228 | 0.000 |
Why?
|
| Binding Sites | 1 | 1992 | 6022 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1994 | 2781 | 0.000 |
Why?
|
| Exercise | 1 | 2000 | 5955 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1984 | 493 | 0.000 |
Why?
|
| Hypertension, Pulmonary | 1 | 1994 | 1605 | 0.000 |
Why?
|
| Complement Activating Enzymes | 1 | 1982 | 22 | 0.000 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1994 | 1483 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1983 | 411 | 0.000 |
Why?
|
| Respiration, Artificial | 1 | 1994 | 2726 | 0.000 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1983 | 338 | 0.000 |
Why?
|
| Complement C1q | 1 | 1982 | 93 | 0.000 |
Why?
|
| Ranidae | 1 | 1982 | 32 | 0.000 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1981 | 29 | 0.000 |
Why?
|
| Thyroxine | 1 | 1984 | 666 | 0.000 |
Why?
|
| Interview, Psychological | 1 | 1984 | 811 | 0.000 |
Why?
|
| Immunoglobulins | 1 | 1984 | 854 | 0.000 |
Why?
|
| Veterans | 1 | 1994 | 2669 | 0.000 |
Why?
|
| Random Allocation | 1 | 1985 | 2396 | 0.000 |
Why?
|
| Depressive Disorder | 1 | 1993 | 3721 | 0.000 |
Why?
|
| Delayed-Action Preparations | 1 | 1984 | 968 | 0.000 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 1981 | 241 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1993 | 5536 | 0.000 |
Why?
|
| Dehydroepiandrosterone | 1 | 1981 | 259 | 0.000 |
Why?
|
| Clomiphene | 1 | 1979 | 72 | 0.000 |
Why?
|
| Congenital Abnormalities | 1 | 1984 | 703 | 0.000 |
Why?
|
| Biological Assay | 1 | 1982 | 627 | 0.000 |
Why?
|
| Polyethylene Glycols | 1 | 1984 | 1196 | 0.000 |
Why?
|
| Immunoassay | 1 | 1982 | 746 | 0.000 |
Why?
|
| Reference Standards | 1 | 1982 | 1013 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1984 | 1172 | 0.000 |
Why?
|
| Health Education | 1 | 1984 | 1059 | 0.000 |
Why?
|
| Communication | 1 | 1990 | 3904 | 0.000 |
Why?
|
| Testis | 1 | 1979 | 783 | 0.000 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1979 | 703 | 0.000 |
Why?
|
| Insulin | 1 | 1988 | 6606 | 0.000 |
Why?
|
| Cerebellar Neoplasms | 1 | 1978 | 591 | 0.000 |
Why?
|
| Body Weight | 1 | 1979 | 4628 | 0.000 |
Why?
|
| Testosterone | 1 | 1979 | 2491 | 0.000 |
Why?
|
| Rats | 1 | 1982 | 23751 | 0.000 |
Why?
|